FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BE	NEFICIAL OWNERSHIP
----------------------------	--------------------

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Pera Antonio R				2. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ ANIP ]								ck all appl	licable) tor	ng Per	rson(s) to Is	vner			
(Last)	(Fi	rst) (N	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/21/2024									Office below	r (give title		Other (s below)	specify	
C/O ANI PHARMACEUTICALS, INC.					4. If A	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
210 MAIN STREET WEST				and an analysis of Singiliar Field (Moritin Day) (ear)							Line)  X Form filed by One Reporting Person								
(Street)	TTE M	N 5	6623												Form filed by More than One Reporting Person				
JACOBETTE WITH 30025					Rul	Rule 10b5-1(c) Transaction Indication													
(City)	(Si	ate) (Z	Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								n that is inter	nded to					
		Table	I - Non	ı-Deriva	tive S	Secui	rities	Acq	uired,	Disp	oosed of	, or E	Benef	ficial	ly Own	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Exec ay/Year) if any		Deemed cution Date, ly nth/Day/Year)		Transaction Disposed (Code (Instr. 5)		ies Acquired (A Of (D) (Instr. 3,			Benefic Owned	ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
										v	Amount	(A) (D)	or P	rice	Transac	Reported Fransaction(s) Instr. 3 and 4)			(Instr. 4)
Common Stock 05/21/2					2024			<b>A</b> <sup>(1)</sup>		4,410	A	A	\$ <mark>0</mark>	31,037			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/I		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		S (I	. Price of derivative lecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	Ownersh Form: y Direct (D or Indire (I) (Instr.	Ownership	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amou or Numb of Share	per					

## **Explanation of Responses:**

1. Represents a restricted stock award that will vest in full on May 21, 2025.

## Remarks:

/s/ Antonio R. Pera, by attorney-in-fact Meredith W. Cook

05/23/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.